Table 5 Best response in patients by EGFR mutations
From: Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
| Â | Gefitinib/Erlotinib | Afatinib | Osimertinib | |||
|---|---|---|---|---|---|---|
Exon 19 del n (%) | L858R n (%) | Exon 19 del n (%) | L858R n (%) | Exon 19 del n (%) | L858R n (%) | |
Totala | 69 | 100 | 42 | 10 | 63 | 71 |
Best Response | ||||||
 CR | 11 (15.9) | 6 (6.0) | 3 (7.1) | 2 (20.0) | 3 (4.8) | 2 (2.8) |
 PR | 35 (50.7) | 64 (64.0) | 21 (50.0) | 5 (50.0) | 45 (71.4) | 49 (69.0) |
 SD | 16 (23.2) | 22 (22.0) | 14 (33.3) | 1 (10.0) | 9 (14.3) | 17 (24.20) |
 PD | 7 (10.1) | 8 (8.0) | 4 (9.5) | 2 (20.0) | 6 (9.5) | 3 (4.2) |
ORR | 46 (66.7) | 70 (70.0) | 24 (57.1) | 7 (70.0) | 48 (76.2) | 51 (71.8) |
DCR | 62 (89.9) | 92 (92.0) | 38 (90.5) | 8 (80.0) | 57 (90.5) | 68 (95.8) |